Immunexpress.com

Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic…

Read More
Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine’s (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb. 12, 2021. The presentation highlights…

Read More
Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data demonstrating performance, reproducibility and identification of fungal infections, in two poster presentations at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo on Nov. 16-20.   “Our SeptiCyte® technology leverages host-response gene-expression biomarkers…

Read More
Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that it will present data in two posters and host a workshop at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo taking place virtually on Nov. 16-20, 2020.   Details of the presentations are as follows:…

Read More
Immunexpress.com

Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients SEATTLE, Sept. 23, 2020 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today new data in collaboration with researchers at the University College of London. …

Read More
Immunexpress.com

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled “Clinical Performance of a Rapid Sepsis…

Read More
Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), of up to $599,549 to…

Read More
Immunexpress.com

Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe   SEATTLE and BRISBANE, March 26, 2020 – Immunexpress,…

Read More
Immunexpress.com

Immunexpress, Pty Ltd & Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems. The scope of the certification includes the design and…

Read More
Immunexpress.com

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that its Chief Executive Officer, Rolland Carlson, Ph.D., will present at Biotech Showcase 2020, to be held January 13-15 at the Hilton San Francisco Union Square. Dr. Carlson will present an overview of the Company’s SeptiCyte™ technology and the…

Read More